Fluorescence polarization (FP) is an established technique for the study of biological interactions and is frequently used in the high-throughput screening (HTS) of potential new drug targets. This work describes the miniaturization of FP receptor assays to 1536-well formats for use in HTS. The FP assays were initially developed in 384-well microplates using CyDye-labeled nonpeptide and peptide ligands. Receptor expression levels varied from~1 to 10 pmols receptor per mg protein, and ligand concentrations were in the 0.5-to 1.0-nM range. The FP assays were successfully miniaturized to 1536-well formats using Cy3B-labeled ligands, significantly reducing reagent consumption, particularly the receptor source, without compromising assay reliability. Z′ factor values determined for the FP receptor assays in both 384-and 1536-well formats were found to be > 0.5, indicating the assays to be robust, reliable, and suitable for HTS purposes. (Journal of Biomolecular Screening 2003:410-420) Key words: fluorescence polarization, high-throughput screening, CyDye-labeled nonpeptide and peptide ligands, miniaturization of FP receptor assays MATERIALS l-Quinuclidyl[phenyl-4-3 H]benzilate ([ 3 H]QNB), [ 125 I]-Bolton-Hunter Sub P, Type B polyethylenimine (PEI) wheatgerm 410 www.sbsonline.org
INTRODUCTION
I n the past, radioligand binding techniques such as filtration or scintillation proximity assay (SPA) have been used for highthroughput screening (HTS) of cell surface G-protein-coupled receptors (GPCRs) and ligand gated channels. Increasingly, there has been a move away from such radioactive technologies toward chemiluminescence and fluorescence, and recent studies have shown that fluorescence polarization (FP), using fluor-labeled peptide or nonpeptide ligands, is a viable alternative. Early fluorescence polarization receptor-binding studies have been confined to cuvette-based, low-throughput investigation of receptor kinetics and steady-state binding 1 or to the characterization of ligand binding sites using peptide or nonpeptide ligands labeled with environmentally sensitive fluors. 2 More recently, advances in dye chemistries and the introduction of sensitive FP plate readers, capable of accurate measurements in 384-well plates, have led to the development of high-throughput FP receptor assays suitable for HTS. [3] [4] [5] [6] Our studies have concentrated on 2 important and widely studied GPCRs expressed in Chinese hamster ovary (CHO) cellsnamely, the M 1 muscarinic acetylcholine (M 1 AchR) receptor 7 and the neurokinin-1 (NK 1 -R) receptor. 8 Recent experiments involving M 1 null mutant mice suggest that M 1 AchRs in the hippocampus and forebrain are specifically involved in memory processes. 9 The Substance P/NK 1 -R system is the most extensively studied neuropeptide pathway of the nervous system, and studies have suggested that selective inhibition of this pathway may lead to useful therapies for the treatment of depression and anxiety. 10 We have described previously the development of a 96-well FP receptor assay ( Fig. 1) , using a CyDye-labeled nonpeptide antagonist and CHO cells expressing the M 1 AchR. 11 Here we describe the miniaturization of this M 1 AchR FP assay to a 384-well format 12 using the CyDye-labeled nonpeptide ligand. In addition, the sitespecific labeling of the Substance P (Sub P) peptide with Cy3B and the development of a 384-well FP receptor assay 13 using the labeled peptide and CHO cells expressing the NK 1 -R are described. Data that illustrate the further miniaturization of these FP receptor assays to 1536-well formats are also described, using the Cy3Blabeled nonpeptide and peptide ligands. This miniaturization significantly reduced reagent consumption without compromising assay reliability. agglutinin (WGA) SPA beads, Cy5 monofunctional NHS ester, and Cy3B monofunctional NHS ester were from Amersham Biosciences UK Limited (Little Chalfont, Bucks, UK).
Pefabloc SC was from Roche Molecular Biochemicals (Lewes, East Sussex, UK); complete HAMS F12 media (N4888) and complete MEM (α modification) media (M4526) were from Sigma-Aldrich Chemical Co. (Poole, Dorset, UK); Coomassie Plus Protein Reagent and bovine serum albumin (BSA) protein standard were from Pierce (Rockford, IL); Ultra-Turrax T8 homogenizer was from IKA Labortechnik (Staufen, Germany); clear 96-well microplates were from Nunc (Naperville, CA); clear-bottom, white 96-well nonbinding surface microplates and black 384-well nonbinding surface microplates were from Corning Life Sciences (Corning, NY); and black medium-binding polystyrene 1536-well FLUOTRAC 200 microplates were from Greiner Labortechnik (Stonehouse, Glos, UK). Meltilex solid scintillator, Filtermat A (GF/C), sample bags, and the Meltilex HeatSealer were from PerkinElmer Life Sciences (Boston, MA). All other reagents were obtained from Sigma-Aldrich Chemical Company (Poole, Dorset, UK).
METHODS

Preparation of Chinese hamster ovary cell membranes M 1 AchR cells
CHO cells expressing human M 1 AchRs were grown to confluency in 200 mL of complete HAMS F12 media in roller flasks. When confluent, cells were harvested by manual scraping into phosphate-buffered saline (PBS) precooled to 4 to 10°C. Cells were centrifuged at 1200 × g for 5 min at 4 to 10°C in a refrigerated bench-top centrifuge. Pelleted cells were resuspended in 40 mL homogenization buffer (5 mM MgCl 2 , 50 mM Tris pH 7.5), placed on ice, and homogenized using the Ultra-Turrax T8 homogenizer for 3 bursts of 20 sec (maximum setting, 6) with 10-sec intervals. The homogenate was then centrifuged at 1200 × g for 5 min and the supernatant retained and stored on ice. The pellet was rehomogenized as described above, and the centrifugation was repeated. The supernatants were combined and centrifuged at 39,000 × g in the Beckman J2-21/ME centrifuge (Beckman Coulter, Fullerton, CA) for 30 min at 4°C. Pellets were resuspended in cold homogenization buffer using a handheld Teflon/glass homogenizer and centrifuged again at 39,000 × g as described above. Finally, the pellets were resuspended in~12 mL homogenization buffer using the Teflon/glass homogenizer, and 0.5-mL aliquots of the membrane preparation were frozen and stored at -80°C.
NK 1 -R cells
CHO cells expressing human NK 1 -Rs were grown to confluency in 200 mL of complete MEM (α modification) media in roller flasks. When confluent, cells were harvested by manual scraping into PBS precooled to 4 to 10°C. Cells were centrifuged at 1200 × g for 5 min at 4 to 10°C in a refrigerated bench-top centrifuge. Pelleted cells were resuspended in 40 mL homogenization buffer (0.32 M sucrose, 1 mM EDTA, and 50 mM Tris pH 7.5 with 1 mM Pefabloc SC). For preservation of this receptor, it was also necessary to include a protease inhibitor cocktail (400 µg/mL bacitracin and 20 µg/mL leupeptin). This cocktail was included in subsequent buffers used (as described in the text). Cells were placed on ice and homogenized using the Ultra-Turrax T8 homogenizer for 3 bursts of 30 sec (maximum setting, 6) with 30-sec intervals. The homogenate was then centrifuged at 1200 × g for 5 min and the supernatant retained and stored on ice. The pellet was rehomogenized as described above, and the centrifugation was repeated. The supernatants were combined and centrifuged at 39,000 × g in the Beckman J2-21/ME centrifuge for 30 min at 4°C.
Pellets were resuspended in 10 mL wash buffer (50 mM Tris pH 7.5 with 1 mM Pefabloc SC, 400 µg/mL bacitracin, and 20 µg/mL leupeptin) using a handheld Teflon/glass homogenizer and centrifuged again at 39,000 × g as described above.
Finally, the pellets were resuspended in 10 to 12 mL cold wash buffer using the Teflon/glass homogenizer, and 0.5-mL aliquots of the membrane preparation were frozen and stored at -80°C.
Protein determination
Following solubilization of the membrane preparations using 1% Triton-X-100 and dilution to eliminate interference from the detergent, the protein concentrations were determined using the Pierce Coomassie Plus Protein Reagent in microassays using 96well clear microplates. In each case, a range of standard dilutions of BSA was used to generate a standard curve.
Determination of receptor expression levels
The receptor expression levels of the CHO cell membrane fractions were determined by radioactive saturation binding experiments using a range of concentrations of the radiolabeled ligand. Following incubation at room temperature for 3 h in 0.1% BSA, 5 mM MgCl 2 , 50 mM Tris pH 7.5 (total assay volume = 200 µL), receptor-bound ligand was separated from free ligand by filtration onto Filtermat A using the Skatron Micro96 harvester (Skatron Instruments, Tranby, Norway). After sealing the filtermat onto Meltilex scintillant within a sample bag, counts were determined using an EG&G Wallac 1205 Betaplate scintillation counter (PerkinElmer Life Sciences). Receptor expression levels (B max ) were determined from the Scatchard plot generated using Prism software, version 3.0 (GraphPad Software, Inc., San Diego, CA).
NK 1 -R
This was performed using SPA, which required the initial characterization of the detection system. Briefly, the efficiency for SPA was determined using known amounts of [ 125 I]-Bolton-Hunterlabeled SPA beads. The amount of [ 125 I]-Sub P bound in the receptor assays was then determined from the SPA counts observed in the assays in comparison with these [ 125 I]-standards. NK 1 -R cell membranes (5 µg) were incubated with a range of concentrations of [ 125 I]-Bolton-Hunter Sub P and 0.5 mg Type B PEI WGA SPA beads. Incubations were performed in sealed plates at room temperature for 3 h in 50 mM Tris pH 7.5, containing 0.5% (w/v) BSA, 1 mM EDTA, 1 mM MnCl 2 , 400 µg/mL bacitracin, 20 µg/mL leupeptin, and 1 mM Pefabloc SC (total assay volume = 200 µL) in 96-well clear-bottom white nonbinding surface plates. NSB was determined in the presence of 25 µM Sub P. The assay plate was counted using the EG&G Wallac 1450 MicroBeta TriLux scintillation counter (PerkinElmer Life Sciences). Receptor expression levels (B max ) were determined from the Scatchard plot generated using the Prism software.
CyDye labeled nonpeptide and peptide ligands
Labeling of M 1 AchR nonpeptide ligands
Activated esters of Cy3B and Cy5 were individually coupled in the solution phase to an amine-functionalized derivative of the M 1 AchR antagonist telenzepine, telenzepine amine congener. 14 Following purification by reverse-phase high-performance liquid chromatography (HPLC), purity was confirmed by mass spectrometry.
Synthesis and labeling of NK 1 -R peptide ligands
Sub P peptides, Ac-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 and H-Arg-Pro-Lys(Ac)-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 , were synthesized from solid phase using Fastmoc chemistry (Applied Biosystems, Foster City, CA) on an automated peptide synthesizer. Acetylation at the N-terminus and ε-lysine allowed site-specific labeling of the Sub P peptides. Cy3B was introduced on the solid phase via in situ activation, and the la-beled peptide was cleaved from the solid phase and purified by conventional reverse-phase HPLC. The following lyophilized products were subsequently characterized by UV and MALDI-TOF mass spectrometry:
Determination of the relative affinities of the labeled ligands
The relative affinities, based on IC 50 , of the Cy5-and Cy3Blabeled nonpeptide and peptide ligands used in this study were determined by radioactive, competitive assays (either by filtration or SPA methods, described below) using the appropriate receptor source and radiolabeled ligand. IC 50 values determined by competitive binding experiments were used to determine the rank order of potency of the labeled and unlabeled ligands and subsequently to describe their relative affinities. 
Development of 384-well FP receptor assays M 1 AchR FP assay
Matrix experiments were performed to generate dose-response curves, varying the amounts of either M 1 AchR cell membrane preparation (~10 pmols receptor/mg protein) or the concentration of Cy5-or Cy3B-telenzepine. Incubations were performed in a total volume of 50 µL in assay buffer (50 mM Tris pH 7.5 containing 0.1% BSA, 5 mM MgCl 2 ) in sealed black 384-well nonbinding surface plates (Corning) for 4 h at room temperature (20-25°C). NSB was determined in the presence of 100 µM atropine. As an additional control, parallel binding assays were performed using similar amounts of membranes prepared from CHO cells that did not express the M 1 AchR protein.
Fluorescence polarization was measured on a FARCyte fluorescence plate reader (Amersham Biosciences UK Limited) using either Cy5 (610/20 nm excitation; 670/40 nm emission) or Cy3B (535/25 nm excitation; 590/20 nm emission) optical filter and dichroic configurations. In all experiments, membrane preparation blanks were included, containing the same amount of membrane preparation as the assay wells. The background parallel and perpendicular data obtained for the membrane blanks were subtracted from all raw data prior to the calculation of polarization values. Specific polarization values were then determined by subtracting the polarization signal obtained in the presence of 100 µM atropine from the test well values. Following assay optimization as described above, competitive binding assays were performed by FP using Cy5-and Cy3Btelenzepine. M 1 AchR cell membranes (30 µg for Cy5-telenzepine and 15µg for Cy3B-telenzepine) were incubated with either Cy5telenzepine (1 nM) or Cy3B-telenzepine (1 nM) and varying concentrations of atropine or unlabeled telenzepine using the incubation conditions described above. NSB was determined in the presence of 100 µM atropine. Membrane blanks were included as described previously, and FP was measured on FARCyte. Specific polarization values were then determined by subtracting the polarization signal obtained in the presence of 100 µM atropine from the test well values.
NK 1 -R FP assay
Dose-response curves were produced in a similar way to the M 1 AchR FP assay described above to optimize the 384-well NK 1 -R FP assays. Varying amounts of the NK 1 -R cell membrane preparation (1-2 pmols receptor/mg protein) were incubated with different concentrations of either Cy3B-(lysine)-Sub P or Cy3B-(terminal)-Sub P in black 384-well nonbinding surface plates. Incubations were performed in a total volume of 50 µL in assay buffer (50 mM Tris pH 7.5 containing 0.5% BSA, 1 mM EDTA, 1 mM MnCl 2 , 400 µg/mL bacitracin, 20 µg/mL leupeptin, and 1 mM Pefabloc SC) in sealed plates for 3.5 h at room temperature (20-25°C ), with NSB determined in the presence of 25 µM unlabeled Sub P. Parallel binding assays were performed using membranes prepared from CHO cells that did not express the NK 1 -R protein as an additional control.
FP was measured on FARCyte using Cy3B optical filter/ dichroic configurations. Membrane preparation blanks were included in all experiments containing the same amount of membrane preparation as the assay wells. The background data obtained in this way were subtracted from all raw data prior to the calculation of polarization values. Specific polarization values were then determined by subtracting the polarization signal obtained in the presence of 25 µM Sub P from the test well values.
Competitive binding assays were performed by FP using the Cy3B-labeled Sub P derivatives. NK 1 -R cell membranes (30 µg) were incubated with either Cy3B-(lysine)-Sub P (0.5 nM) or Cy3B-(terminal)-Sub P (0.5 nM) and varying concentrations of Sub P, [Sar 9 Met(O 2 ) 11 ] Sub P (NK 1 -R specific agonists), or NKA (an NK 2 -R specific agonist, included as a negative control) using the incubation conditions described above. NSB was determined in the presence of 25 µM Sub P. Membrane blanks were included as described previously, and FP was measured on FARCyte. Specific polarization values were then determined as described above.
Miniaturization of FP receptor assays to 1536 wells
The M 1 AchR and NK 1 -R FP 1536-well miniaturized assays required further optimization due to the differences in plate types (and properties) used. This was done by performing dose-response curves, varying the concentrations of both membrane preparation and Cy3B-labeled ligand concentration in a total assay volume of 8 µL. All reagents were added sequentially to the microplate wells using manual pipettors for all 1536-well assays. Following assay optimization, competitive binding experiments were performed. M 1 AchR 1536-well assay M 1 AchR cell membranes (1 µg) were incubated with Cy3Btelenzepine (0.5 nM) and varying concentrations of atropine in a total volume of 8 µL in M 1 AchR assay buffer in black 1536-well plates (Greiner). Assays were incubated in sealed plates for 4 h at room temperature (20-25°C). NSB was determined in the presence of 100 µM atropine. Membrane blanks were included as described previously for the 384-well assays, only using 1 µg cell membrane protein, and FP was measured on FARCyte. Specific polarization values were then determined by subtracting the polarization signal obtained in the presence of 100 µM atropine from the test well values.
NK 1 -R 1536-well assay
NK 1 -R cell membranes (5 µg) were incubated with Cy3B-(terminal)-Sub P (0.5 nM) and varying concentrations of Sub P in a total volume of 8 µL in NK 1 -R assay buffer in black 1536-well plates. Assays were incubated in sealed plates for 3.5 h at room temperature (20-25°C). NSB was determined in the presence of 25 µM Sub P. Membrane blanks were included as described previously, and FP was measured on FARCyte. Specific polarization values were then determined by subtracting the polarization signal obtained in the presence of 25 µM Sub P from the test well values.
Z factor determination
Z′ factor analysis, originally described by Zhang et al, 15 was performed for the M 1 AchR and NK 1 -R FP assays in both 384-and 1536-well formats using the appropriate Cy5-or Cy3B-labeled ligand and assay buffer. Replicate (> 150) test wells and NSB wells
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were used, and all reagents were added sequentially to the 384well or 1536-well plates with manual pipettors (see legends to Figs. 7 and 8). Total assay volumes were 50 µL for 384-well plates and 8 µL for 1536-well plates, and as for all other experiments, appropriate membrane blanks were included on the assay plates to obtain the background data. Fluorescence polarization was measured on FARCyte, using either Cy5 or Cy3B optical filter/ dichroic configurations as appropriate, and polarization values were calculated following subtraction of the background data.
DMSO tolerance of NK 1 -R FP assay NK 1 -R cell membranes (30 µg), 0.5 nM Cy3B-(terminal)-Sub P, and varying amounts of DMSO (0.5%-10% (v/v) final concentration) were incubated in sealed black 384-well nonbinding surface plates in a total volume of 50 µL in assay buffer (0.5% BSA, 1 mM EDTA, 1 mM MnCl 2 , and 50 mM Tris pH 7.5 containing 400 µg/mL bacitracin, 20 µg/mL leupeptin, and 1 mM Pefabloc SC) for 3.5 h at room temperature (20-25°C). NSB was determined in the presence of 25 µM unlabeled Sub P. The DMSO was added either at the start of the assay incubation or following completion of the binding reaction. FP was measured on FARCyte using Cy3B optical filter/dichroic configurations. Membrane preparation blanks were included as described in the previous experiments, and the background values were subtracted from all raw data prior to the calculation of polarization values. Specific polarization values were then determined by subtracting the polarization signal obtained in the presence of 25 µM Sub P from the test well values.
RESULTS AND DISCUSSION
Prior to the optimization and development of the FP assays, the receptor expression levels of both the M 1 AchR and NK 1 -R cell membranes were determined by radioactive saturation binding. B max values (derived from Scatchard plots using GraphPad Prism software) were found to be in the region of 10 pmols receptor/mg protein for the M 1 AchR cell membranes and 1 to 2 pmols receptor/ mg protein for the NK 1 -R cell membranes (data not shown).
Determination of the relative ligand affinities, based on IC 50
A critical factor in the successful development of FP receptor assays is the maintenance of binding affinity following the labeling of the ligand with fluorescent dyes. The coupling of a large fluorescent label may sterically hinder the binding of the labeled ligand to the receptor, drastically reducing binding affinity. This is particularly relevant if the ligand is a small nonpeptide molecule with only 1 possible coupling site. The successful fluorescent labeling of low molecular weight ligands for other receptors, such as β 2adrenoceptor 16 and 5-hydroxytryptamine 3 (5-HT 3 ) receptor, 17 has been reported previously. In addition, these BODIPY-FL and fluorescein-labeled ligands have been used in the development of FP receptor assays. 4 Accordingly, the relative affinities, based on IC 50 , of the Cy5and Cy3B-labeled nonpeptide and peptide ligands used in this study were determined by radioactive, competitive binding assays using the appropriate receptor source and radiolabeled ligand. Table 1 shows the IC 50 values generated for Cy5-and Cy3Btelenzepine compared with those for unlabeled telenzepine and telenzepine amine congener. Labeling the telenzepine amine congener with Cy3B did not affect the relative affinity, based on IC 50 , measured in this way, whereas the coupling of Cy5 reduced the relative affinity, based on IC 50 , by 4-fold.
Peptide ligands often have more available sites for successful coupling of fluorescent labels than small-molecule ligands. However, it is important to label at a residue where binding to the receptor will not be impeded. The Sub P peptide was labeled at 2 different positions. The site-specific labeling of the peptide with Cy3B was achieved by in situ activation after the initial blocking of other possible labeling sites by acetylation at either the N-terminus or the ε-lysine residue. The relative affinities, based on IC 50 , of both the Cy3B-labeled purified peptides were determined by radioactive competitive binding using SPA ( Table 2 ). Labeling with Cy3B at the N-terminus resulted in an 11-fold reduction in the relative affinity, based on IC 50 , whereas a larger decrease in the relative affinity, based on IC 50 (~30-fold), was observed when the ε-lysine residue was labeled. Importantly, the relative binding affinities, based on IC 50 , of all the CyDye-labeled ligands used for the FP receptor assays remained in the nanomolar range.
Development of 384-well FP assays
The M 1 AchR and NK 1 -R FP assays were initially optimized and characterized in 384-well assay plates. Dose-response curves were performed for each of the assays, and representative data are shown for the M 1 AchR FP assay using both Cy5-and Cy3Btelenzepine ( Fig. 2a,b) . To maximize the polarization signal window while retaining the ability to successfully investigate competi- tion binding, it was found that 30 µg M 1 AchR cell membrane was required for the assay using Cy5-telenzepine. However, with Cy3B-telenzepine, the amount of membrane protein required for the FP assay was the same as that used in the radioactive receptorbinding assay (15 µg) . When CHO cell membranes that did not express the M 1 AchR protein were used in similar binding experiments, no specific binding was detected ( Fig. 2a,b) . Ligand concentrations were low, in the range 0.5 to 1.0 nM, as a substantial proportion of the ligand needs to be bound to the receptor to produce a significant change in FP signal. It is therefore vital that the FP instrumentation used has the necessary sensitivity to accurately and reproducibly detect such low concentrations. Instruments such as the FARCyte fluorescence plate reader, in the polarization mode, have subnanomolar levels of detection with standard deviations (SD) of < 10 mP. At higher concentrations (as used in these assays), the standard deviations are less than 4 mP. FARCyte therefore has the sensitivity and reproducibility for these miniaturized FP receptor assays.
Following FP assay optimization, competitive binding assays were performed using appropriate amounts of M 1 AchR cell membrane and 1.0 nM of either Cy5-or Cy3B-telenzepine. Figures 3a (Cy5-telenzepine) and 3b (Cy3B-telenzepine) shows the competitive binding curves obtained with both atropine and unlabeled telenzepine. Maximal change in the specific FP signal was observed using Cy3B-telenzepine, with an overall signal window (max FP -min FP) of approximately 180 mP, but consistent results were obtained with both labeled ligands.
Similar competitive binding experiments were performed following optimization of the NK 1 -R FP assay (data not shown). Optimization included parallel binding experiments using CHO cell membranes that did not express the NK 1 -R protein. No specific binding was observed with these membranes. Optimization experiments suggested that 30 µg NK 1 -R cell membrane was required for the FP assay using either the Cy3B-(terminal)-Sub P or Cy3B-(lysine)-Sub P ligands (0.5 nM).
The competitive binding curves obtained with Sub P, [Sar 9 Met(O 2 ) 11 ] Sub P, and NKA are shown in Figure 4a 
Polarization (mP)
as the ligand for the further miniaturization of the NK 1 -R FP assay to 1536-well plates.
Miniaturization of FP receptor assays to 1536-well plates
The M 1 AchR and NK 1 -R FP assays were adapted and reoptimized (as described in the text) for use in 1536-well plates by reducing the assay volume to 8 µL and significantly decreasing the amount of membrane protein required for the assays (see Tables 3  and 4 ). Table 3 summarizes the different assay formats for the M 1 AchR FP receptor assay, initially developed in 96-well microplates, 11 for both Cy3B-telenzepine (Table 3a) and Cy5telenzepine (Table 3b ). In successfully adapting the FP assay from 96-to 1536-well microplates using the Cy3B-labeled ligand, there was a 25-fold reduction in assay volume, with a concomitant 50fold reduction in cell membrane and a 40-fold reduction in labeled ligand consumption.
The competitive binding curve in 1536-well plates using Cy3Btelenzepine and atropine is shown in Figure 5 . Similar specific polarization and apparent IC 50 values were observed in both the 384and 1536-well assays. The overall signal window obtained for the 1536-well FP assay was approximately 160 mP, comparable to that observed in the 384-well assay (Fig. 3b) . Table 4 summarizes the assay conditions for the miniaturization of the NK 1 -R FP assay from 384 to 1536 wells using the Cy3B-(terminal)-Sub P peptide. The assay volume was reduced to 8 µL, resulting in an approximate 6-fold reduction in both membrane and Cy3B-labeled peptide consumption. The competitive binding curve generated using the Cy3B-(terminal)-Sub P peptide and unlabeled Sub P in 1536 well plates is shown in Figure 6 . As for the M 1 AchR FP assay, similar specific polarization and apparent IC 50 values were observed in both the 384-and 1536-well NK 1 -R FP assays. The maximal signal window of 80 mP is similar to that observed in the 384-well assay (Fig. 4a ).
Z factor determination in 384-well and 1536-well assays
The reliability of the 384-and 1536-well receptor FP assays was tested by performing Z′ factor analysis as described originally by Zhang et al. 15 Assays with a Z′ factor between 0.5 and 1.0 are considered to be reliable, robust, and suitable for HTS. 15 Replicate (> 150 wells) B 0 and NSB wells were used for both M 1 AchR and NK 1 -R FP assays in both 384 and 1536 plate formats, and all reagents were added sequentially to the assay wells using manual pipettors (see Methods section). 
Specific Polarization (mP)
Well-by-well plots of the Z′ factor determination for the M 1 AchR FP assay are shown in Figure 7a -c. Z′ factor analysis was performed using both Cy5-and Cy3B-telenzepine in 384-well plates (Fig. 7a,b ) and using Cy3B-telenzepine in 1536-well plates (Fig. 7c ). In each case, the Z′ factor determined was > 0.5 (see Tables 3a and 3b), suggesting that the 384-and 1536-well M 1 AchR FP assays are suitable for HTS purposes. Figure 8a,b shows the well-by-well plots for the Z′ factor analysis of the NK 1 -R FP assay using the Cy3B-(terminal)-Sub P peptide in both 384-well ( Fig.  8a) and 1536-well plates (Fig. 8b) . Values determined in both assay formats were > 0.5 (see Table 4 ), indicating that both these assays are suitable for HTS purposes.
DMSO tolerance of NK 1 -R FP assay
To assess the full applicability of the FP assays for HTS, it is necessary to test the effect of low concentrations of solvents, such as DMSO, that are used to solubilize test compounds prior to the addition to screening assays. We have tested the effect of different concentrations of DMSO on the 384-well NK 1 -R FP assay. The results are shown in Figure 9 . The assay tolerated up to 2.5% (v/v) DMSO. Higher DMSO concentrations resulted in a reduction in the specific polarization signal (Fig. 9a ). This is thought to be due to a direct effect on the binding interaction itself as when DMSO was added following equilibration of the binding incubation, only minimal effects on the specific polarization signal were observed even at 10% (v/v) DMSO (Fig. 9b ).
CONCLUSIONS
We have demonstrated the development and characterization of 2 FP receptor assays using CyDye-labeled nonpeptide and peptide ligands. One critical factor in the successful development of these assays is the maintenance of binding affinity following the labeling of the ligand with the fluorescent dyes. We have shown that by using both nonpeptide and peptide ligands labeled with Cy5 and Cy3B, it is possible to develop FP receptor assays. We observed minimal effect on the relative affinities, based on IC 50 , of the ligands for their receptor and were able to use commonly achievable receptor expression levels in the order of 1 pmol receptor/mg protein.
We found that the Cy3B-labeled ligands gave the greater specific polarization values in the 384-well assays, and accordingly, these ligands were used for the further miniaturization of the FP receptor assays to 1536-well formats. The reason for this superior specific signal has not been fully investigated; it may arise from the differences in the fluorescence lifetimes of the 2 fluors (2.8 and 1.0 nsec for Cy3B and Cy5, respectively). This results in a higher intrinsic polarization value for free Cy5 alone (approximately 170 mP) compared to Cy3B (approximately 50 mP). Furthermore, upon conjugation of the fluor to the ligand, there is a greater increase in polarization value observed for the free ligand above the free dye for Cy5, perhaps resulting in a reduction in the observed assay window on binding to the receptor. Another reason may be differences in the "limiting" (or P o ) polarization value for the fluor. 18 Similar findings have been observed by other groups 19 who postulated that the improved assay window may well be due to a higher P o value for Cy3B. In addition, the demonstration of Cy3B as the optimum label may have additional benefits for compound screening applications, as Turconi et al. 19 further suggested in their miniaturized FP screening assays. This group demonstrated that the extent of autofluorescence artifacts in their ultra-high-throughput FP screen was far less with Cy3B as the fluorescent label than if BODIPY-FL were used. We compared the activity of Sub P labeled with Cy3B at 2 different positions and found that the Cy3B-(terminal)-Sub P was preferable to the lysine-labeled peptide for the NK 1 -R FP assay.
We have demonstrated that the use of instrumentation (such as FARCyte), which is sensitive and capable of accurate measure-ments in higher density well plates, has facilitated the 384-well FP assays for both M 1 AchR and NK 1 -R to be successfully miniaturized to 1536-well formats using the Cy3B-labeled nonpeptide and peptide ligands. It was found that the 1536-well assays gave similar maximal signal windows and apparent IC 50 values to the 384well assays. Z′ factor analysis performed for the FP receptor assays in both 384-well and 1536-well formats demonstrated that the Z′ factor was greater than 0.5, indicating that these assays are robust and reliable. Further demonstration of the suitability for performing these assays on imaging instrumentation, such as the LEADseeker multimodality imaging system, 20 tial for the use of FP receptor-binding assays as HTS and ultra-HTS applications.
